Assembly Biosciences (NASDAQ:ASMB) Stock Rating Cut to Sell at Wall Street Zen

Assembly Biosciences (NASDAQ:ASMB – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also commented on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Mizuho set a $53.00 target price on shares of Assembly Biosciences in a report on Tuesday, September 1st. UBS Group decreased their target price on shares of Assembly Biosciences from $52.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday, November 3rd. Zacks Research cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Thursday, October 15th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.50.

Check Out Our Latest Research Report on Assembly Biosciences

Assembly Biosciences Trading Down 1.4%

Shares of ASMB opened at $22.19 on Friday. The firm has a market cap of $454.45 million, a PE ratio of 26.28 and a beta of 1.26. The company’s 50 day simple moving average is $22.17 and its 200-day simple moving average is $26.73. Assembly Biosciences has a 12-month low of $19.20 and a 12-month high of $39.65.

Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last announced its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.27). Assembly Biosciences had a negative net margin of 16.57% and a negative return on equity of 4.40%. The business had revenue of $2.96 million during the quarter, compared to analyst estimates of $9.07 million. As a group, equities research analysts forecast that Assembly Biosciences will post 1.36 EPS for the current fiscal year.

Insider Buying and Selling at Assembly Biosciences

In other news, insider Nicole S. White sold 2,593 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $19.62, for a total value of $50,874.66. Following the completion of the sale, the insider owned 59,257 shares in the company, valued at approximately $1,162,622.34. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Anuj Gaggar sold 2,593 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $19.62, for a total transaction of $50,874.66. Following the completion of the sale, the insider owned 53,800 shares of the company’s stock, valued at $1,055,556. This trade represents a 4.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 12,115 shares of company stock valued at $237,696. 3.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership lifted its position in Assembly Biosciences by 4.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock valued at $1,095,000 after purchasing an additional 1,634 shares during the period. American Century Companies Inc. increased its position in Assembly Biosciences by 35.0% during the 3rd quarter. American Century Companies Inc. now owns 17,869 shares of the biopharmaceutical company’s stock worth $420,000 after purchasing an additional 4,630 shares during the period. Bank of America Corp DE raised its stake in shares of Assembly Biosciences by 113.3% during the 1st quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock worth $303,000 after buying an additional 5,792 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Assembly Biosciences by 69.4% during the 1st quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 6,411 shares in the last quarter. Finally, Engineers Gate Manager LP raised its stake in shares of Assembly Biosciences by 88.5% during the 2nd quarter. Engineers Gate Manager LP now owns 17,766 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 8,343 shares in the last quarter. 19.92% of the stock is owned by hedge funds and other institutional investors.

Key Assembly Biosciences News

Here’s some of the latest news about ASMB:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $50 price target, offering a bullish counterpoint to its forecast reductions. MarketBeat coverage
  • Negative Sentiment: The analyst lowered FY2026 EPS expectations from $2.28 to $1.36 and FY2027 from $0.05 to a loss of $0.71 per share. It also cut estimates for Q4 2026 and several 2027 quarters, and reduced its FY2028 estimate from $0.84 to $0.49. Broad downward revisions may weigh on sentiment toward ASMB. MarketBeat coverage

About Assembly Biosciences

(Get Free Report)

Assembly Biosciences is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus. The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.

Further Reading

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.